COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01280734
Recruitment Status : Completed
First Posted : January 21, 2011
Last Update Posted : December 13, 2011
Information provided by (Responsible Party):
Neurim Pharmaceuticals Ltd.

Brief Summary:
This is a randomised, double-blind, 3-way crossover, single dose, placebo-controlled study investigating the effect on night time awakening body sway of melatonin and zolpidem in healthy adult subjects aged of 55 to 64 years.

Condition or disease Intervention/treatment Phase
Postural Instability Drug: Circadin (R) 2 mg Drug: Stilnox (R) 10 mg Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: Randomised, Double-blind, 3-way Crossover, Single Dose, Placebo-controlled Study Investigating the Effect on Postural Instability of Melatonin and Zolpidem in Healthy Adult Subjects Aged of 55 to 64 Years.
Study Start Date : January 2011
Actual Primary Completion Date : April 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Melatonin
Circadin(R) 2 mg tablet 2 hours at 23:00
Drug: Circadin (R) 2 mg
One 2 mg tablet at 23:00

Active Comparator: Zolpidem
Stilnox (R) 10 mg tablet at 23:00
Drug: Stilnox (R) 10 mg
One 10 mg encapsulated tablet at 23:00

Placebo Comparator: Placebo Drug: Placebo
One tablet or encapsulated tablet at 23:00

Primary Outcome Measures :
  1. Body sway [ Time Frame: 4 hours post IMP adminstration ]

Secondary Outcome Measures :
  1. Body Sway [ Time Frame: 1.5 hours post administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. The subject must have signed an informed consent form.
  2. The subject is a healthy man or woman. Women of child bearing potential or within two years of menopause must have negative urine pregnancy test at screening and use contraceptives as indicated in the protocol.
  3. The subject is 55 to 64 years of age (extremes included).
  4. The subject has a BMI >19 kg/m2 and < 30 kg/m2 at the Screening Visit.
  5. The subject has a normal circadian rhythm, defined as a person who usually wakes between 06:00 and 09:00 and goes to sleep between 21:00 and 24:00.
  6. The subject is, in the opinion of the investigator, generally healthy based on assessment of medical history and examination at screening
  7. The subject is affiliated with, or beneficiary of a social security system.

Major Exclusion Criteria:

  1. The subject has taken disallowed medication within 1 week prior to the first dose of IMP (or within 5 half-lives prior to admission for any medication ingested, whichever is longer). Disallowed medication is any prescribed medication or over-the-counter (OTC) medication as well as any herbal medicine known to interfere with the metabolic CYP pathways, such as St. John's Wort (except for hormonal contraceptives or hormonal substitution therapy). Subjects who have taken any non-prescribed systemic or topical medication may still be entered into the study if, in the opinion of the investigator, the medication will not interfere with the study procedures, study results, or compromise safety.
  2. The subject weighs >136 kg.
  3. The subject cannot stand erect and unsupported for more than 2 to 3 minutes or loses balance when standing on a fixed surface with eyes opened.
  4. The subject has an excessive consumption of beverages on xanthine bases (more than 4 cups or glasses daily).
  5. The subject has a presence or history of alcohol abuse defined as alcohol consumption greater than 21 units per week for men and greater than 14 units per week for women; or a presence or history of drug abuse within the last 6 months, or a history of substance abuse deemed relevant by the investigator.
  6. The subject has taken any investigational products including these IMPs (zolpidem, melatonin) within 3 months prior to admission on Day 1.
  7. The subject has taken these IMPs earlier in this clinical study.
  8. The subject has known hypersensitivity to the melatonin, zolpidem or their excipients.
  9. The subject has a history of severe drug allergy or hypersensitivity.
  10. The subject is pregnant or breastfeeding.
  11. The subject has a presence or history of sleep disorder, fainting, cardiovascular diseases, carotid sinus syndrome, relevant dizziness or arrhythmia.
  12. The subject has a history of or presence of any clinically relevant immunological, cardiovascular, pulmonary, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, systemic, ocular or psychiatric or infectious disease or other major disorder, or sign of acute illness.
  13. The subject has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, which has not been in remission for at least 5 years before the first dose of IMP.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01280734

Layout table for location information
Rouffach, France
Sponsors and Collaborators
Neurim Pharmaceuticals Ltd.
Layout table for additonal information
Responsible Party: Neurim Pharmaceuticals Ltd. Identifier: NCT01280734    
Other Study ID Numbers: Neurim-PIS1
2010-023745-29 ( EudraCT Number )
First Posted: January 21, 2011    Key Record Dates
Last Update Posted: December 13, 2011
Last Verified: December 2011
Keywords provided by Neurim Pharmaceuticals Ltd.:
body sway
postural instability
Additional relevant MeSH terms:
Layout table for MeSH terms
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants